Inovio Pharma stock slips as AstraZeneca unit scales back agreement

Inovio shares fell 6.7% after hours, following a 3.7% decline to close at $3.14. In a filing with the Securities and Exchange Commission, Inovio said AstraZeneca PLC AZN, -0.71% subsidiary MedImmune is discontinuing a research agreement with the company with the exception of a drug candidate known as "MEDI0457."